360 Results

People

  1. Lacouture
    Lacouture
  2. Panageas
    Panageas
  3. Wolchok
    Wolchok
  4. Motzer
    Motzer
  5. Postow
    Postow
  6. Houghton
    Houghton
  7. Zelenetz
    Zelenetz
  8. Balagula
    Balagula
  9. Livingston
    Livingston
  10. Aghajanian
    Aghajanian

Groups

  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)
  7. Dermatology Service (63)
  8. GSK Faculty (53)
  9. Melanoma Disease Management Team (47)
  10. Melanoma and Immunotherapeutics Service (47)
  1. "pruritus"
Formats
  1. Journal Article (336)
  2. Review (15)
  3. Research Letter (3)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (267)
  2. Solid Tumor Oncology Division (171)
  3. Survivorship Research (88)
  4. Division of Subspecialty Medicine (79)
  5. Hematologic Malignancies, Division of (71)
  6. Dermatology (65)

More Groups

People
  1. Mario Lacouture (44)
  2. Jedd Wolchok (29)
  3. Katherine Panageas (16)
  4. Paul Chapman (16)
  5. Robert Motzer (14)
  6. Michael Postow (11)

More People

Years
  1. 2025 (11)
  2. 2024 (38)
  3. 2023 (28)
  4. 2022 (12)
  5. 2021 (16)
  6. 2020 (24)

More Years

Publications
  1. Lancet Oncology (30)
  2. Clinical Cancer Research (17)
  3. Journal of Clinical Oncology (17)
  4. Cancer (11)
  5. Journal of the American Academy of Dermatology (11)
  6. Annals of Oncology (9)

More Publications

Publishers
  1. Elsevier Inc. (46)
  2. Elsevier Science, Inc. (39)
  3. Springer (26)
  4. Nature Publishing Group (22)
  5. American Association for Cancer Research (20)
  6. American Society of Clinical Oncology (18)

More Publishers

Results (360)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: Characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study
    Journal Article

    Rugo, H. S.; Oliveira, M.; Howell, S. J.; Dalenc, F.; Cortes, J.; Gomez, H. L.; Hu, X.; Jhaveri, K. L.; Krivorotko, P.; Loibl, S.; more...
    ESMO Open (2024)

    Fulltext@MSK | Save
  • Mucocutaneous toxicities from MEK inhibitors: A scoping review of the literature
    Review

    Iriarte, C.; Yeh, J. E.; Alloo, A.; Boull, C.; Carlberg, V. M.; Coughlin, C. C.; Lara-Corrales, I.; Levy, R.; Nguyen, C. V.; Oza, V. S.; more...
    Supportive Care in Cancer (2024)

    Fulltext@MSK | Save
  • Phase II study of osimertinib in patients with epidermal growth factor receptor mutations: Results from the NCI-MATCH ECOG-ACRIN (EAY131) trial subprotocol E
    Journal Article

    Chen, M. F.; Song, Z.; Yu, H. A.; Sequist, L. V.; Lovly, C. M.; Mitchell, E. P.; Moscow, J. A.; Gray, R. J.; Wang, V.; McShane, L. M.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
    Journal Article

    Zelenetz, A. D.; Jurczak, W.; Ribrag, V.; Linton, K.; Collins, G. P.; Jiménez, J. L.; Bishton, M.; Dholaria, B.; Mengarelli, A.; Phillips, T. J.; more...
    HemaSphere (2024)

    Fulltext@MSK | Save
  • Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial
    Journal Article

    Gupta, A.; O'Cearbhaill, R. E.; Block, M. S.; Hamilton, E.; Konner, J. A.; Knutson, K. L.; Potts, J.; Garrett, G.; Kenney, R. T.; Wenham, R. M.; more...
    Gynecologic Oncology (2024)

    Fulltext@MSK | Save
  • Evaluating immune checkpoint blockade in metastatic castration-resistant prostate cancers with deleterious CDK12 alterations in the phase 2 IMPACT trial
    Journal Article

    Nguyen, C. B.; Reimers, M. A.; Perera, C.; Abida, W.; Chou, J.; Feng, F. Y.; Antonarakis, E. S.; McKay, R. R.; Pachynski, R. K.; Zhang, J.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • The safety and efficacy outcomes of Minnelide given alone or in combination with paclitaxel in advanced gastric cancer: A phase I trial
    Journal Article

    Lim, S. H.; Saluja, A.; Vickers, S.; Hong, J. Y.; Kim, S. T.; Lavania, S.; Pandey, S.; Gupta, V. K.; Velagapudi, M. R.; Lee, J.
    Cancer Letters (2024)

    Fulltext@MSK | Save
  • Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: A phase 2 trial with biomarker analyses
    Journal Article

    Friedman, C. F.; Manning-Geist, B. L.; Zhou, Q.; Soumerai, T.; Holland, A.; Da Cruz Paula, A.; Green, H.; Ozsoy, M. A.; Iasonos, A.; Hollmann, T.; more...
    Nature Medicine (2024)

    Fulltext@MSK | Save
  • CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: Results of two multi-institutional Phase 1 trials
    Journal Article

    Segal, N. H.; Melero, I.; Moreno, V.; Steeghs, N.; Marabelle, A.; Rohrberg, K.; Rodriguez-Ruiz, M. E.; Eder, J. P.; Eng, C.; Manji, G. A.; more...
    Nature Communications (2024)

    Fulltext@MSK | Save
  • Cutaneous hypersensitivity reactions to immune checkpoint inhibitors
    Editorial

    Storgard, R.; Markova, A.
    Journal of Allergy and Clinical Immunology: In Practice (2024)

    Fulltext@MSK | Save